Papatheodorou P, Minton N, Aktories K, Barth H
Adv Exp Med Biol. 2024; 1435:219-247.
PMID: 38175478
DOI: 10.1007/978-3-031-42108-2_11.
MacTaggart B, Kashina A
Cytoskeleton (Hoboken). 2021; 78(4):142-173.
PMID: 34152688
PMC: 8856578.
DOI: 10.1002/cm.21679.
Simon O, Palma L, Fernandez A, Williams T, Caballero P
Toxins (Basel). 2020; 12(9).
PMID: 32842608
PMC: 7551607.
DOI: 10.3390/toxins12090543.
Tan J, Zhang X, Li D, Liu G, Wang Y, Zhang D
Mol Ther Methods Clin Dev. 2020; 17:894-903.
PMID: 32382585
PMC: 7200613.
DOI: 10.1016/j.omtm.2020.04.014.
Toh H, Lin C, Nakajima S, Aikawa C, Nozawa T, Nakagawa I
Front Cell Infect Microbiol. 2019; 9:398.
PMID: 31850237
PMC: 6893971.
DOI: 10.3389/fcimb.2019.00398.
Targeting ADP-ribosylation as an antimicrobial strategy.
Catara G, Corteggio A, Valente C, Grimaldi G, Palazzo L
Biochem Pharmacol. 2019; 167:13-26.
PMID: 31176616
PMC: 7172630.
DOI: 10.1016/j.bcp.2019.06.001.
Anti-proliferative Effect of C3 Exoenzyme in Fibroblasts is Mediated by c-Jun Phosphorylation.
von Elsner L, Hagemann S, Just I, Rohrbeck A
J Mol Signal. 2018; 12:1.
PMID: 30210577
PMC: 5630077.
DOI: 10.5334/1750-2187-12-1.
Rho-inhibiting C2IN-C3 fusion toxin inhibits chemotactic recruitment of human monocytes ex vivo and in mice in vivo.
Martin T, Moglich A, Felix I, Fortsch C, Rittlinger A, Palmer A
Arch Toxicol. 2017; 92(1):323-336.
PMID: 28924833
PMC: 5773661.
DOI: 10.1007/s00204-017-2058-y.
Molecular Evolutionary Constraints that Determine the Avirulence State of Clostridium botulinum C2 Toxin.
Prisilla A, Prathiviraj R, Chellapandi P
J Mol Evol. 2017; 84(4):174-186.
PMID: 28382496
DOI: 10.1007/s00239-017-9791-y.
The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.
Lahiani A, Yavin E, Lazarovici P
Toxins (Basel). 2017; 9(3).
PMID: 28300784
PMC: 5371862.
DOI: 10.3390/toxins9030107.
Cell Entry of C3 Exoenzyme from Clostridium botulinum.
Rohrbeck A, Just I
Curr Top Microbiol Immunol. 2016; 406:97-118.
PMID: 27832378
PMC: 7122702.
DOI: 10.1007/82_2016_44.
C3 exoenzyme impairs cell proliferation and apoptosis by altering the activity of transcription factors.
von Elsner L, Hagemann S, Just I, Rohrbeck A
Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(9):1021-31.
PMID: 27351882
PMC: 4977334.
DOI: 10.1007/s00210-016-1270-2.
EGA Protects Mammalian Cells from Clostridium difficile CDT, Clostridium perfringens Iota Toxin and Clostridium botulinum C2 Toxin.
Schnell L, Mittler A, Sadi M, Popoff M, Schwan C, Aktories K
Toxins (Basel). 2016; 8(4):101.
PMID: 27043629
PMC: 4848627.
DOI: 10.3390/toxins8040101.
Uptake of clostridium botulinum C3 exoenzyme into intact HT22 and J774A.1 cells.
Rohrbeck A, von Elsner L, Hagemann S, Just I
Toxins (Basel). 2015; 7(2):380-95.
PMID: 25648844
PMC: 4344630.
DOI: 10.3390/toxins7020380.
Tailored cyclodextrin pore blocker protects mammalian cells from clostridium difficile binary toxin CDT.
Roeder M, Nestorovich E, Karginov V, Schwan C, Aktories K, Barth H
Toxins (Basel). 2014; 6(7):2097-114.
PMID: 25029374
PMC: 4113744.
DOI: 10.3390/toxins6072097.
Vimentin mediates uptake of C3 exoenzyme.
Rohrbeck A, Schroder A, Hagemann S, Pich A, Holtje M, Ahnert-Hilger G
PLoS One. 2014; 9(6):e101071.
PMID: 24967582
PMC: 4072758.
DOI: 10.1371/journal.pone.0101071.
Binding of Clostridium botulinum C3 exoenzyme to intact cells.
Rohrbeck A, von Elsner L, Hagemann S, Just I
Naunyn Schmiedebergs Arch Pharmacol. 2014; 387(6):523-32.
PMID: 24584821
DOI: 10.1007/s00210-014-0963-7.
A recombinant fusion toxin based on enzymatic inactive C3bot1 selectively targets macrophages.
Dmochewitz L, Fortsch C, Zwerger C, Vaeth M, Felder E, Huber-Lang M
PLoS One. 2013; 8(1):e54517.
PMID: 23349915
PMC: 3549961.
DOI: 10.1371/journal.pone.0054517.
Rho-ROCK and Rac-PAK signaling pathways have opposing effects on the cell-to-cell spread of Marek's Disease Virus.
Richerioux N, Blondeau C, Wiedemann A, Remy S, Vautherot J, Denesvre C
PLoS One. 2012; 7(8):e44072.
PMID: 22952878
PMC: 3428312.
DOI: 10.1371/journal.pone.0044072.
Molecular and biological characterization of Streptococcal SpyA-mediated ADP-ribosylation of intermediate filament protein vimentin.
Icenogle L, Hengel S, Coye L, Streifel A, Collins C, Goodlett D
J Biol Chem. 2012; 287(25):21481-91.
PMID: 22549780
PMC: 3375569.
DOI: 10.1074/jbc.M112.370791.